Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as a positive allosteric modulator of the GABA-A receptor.
## Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Other seizure types as per local protocol.
## Adult Dosing
* **Lennox-Gastaut Syndrome:** The recommended starting dose is 5 mg twice daily. After 1 week, the dose can be increased to 10 mg twice daily. Further increases may be made weekly by 5 mg to 10 mg twice daily, up to a maximum of 20 mg twice daily.
* **Other Seizure Types:** Dosing varies widely and is dependent on the seizure type and individual patient response. A common starting dose might be 5 mg once or twice daily, titrated upwards as tolerated and effective, with a maximum typically around 30 mg/day, but potentially higher based on clinical judgment and monitoring.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 years and older):**
* Starting dose: 5 mg twice daily.
* After 1 week, increase to 10 mg twice daily.
* Further increases may be made weekly by 5 mg to 10 mg twice daily, up to a maximum of 20 mg twice daily for patients weighing less than 30 kg, or 10 mg twice daily for patients weighing 30 kg or more.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Lower doses may be necessary due to reduced metabolism.
* **Renal Impairment:** Use with caution. Dose adjustments may be considered, though specific guidelines are limited.
* **Concomitant Medications:** Consider potential interactions (see Key Drug Interactions).
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, and drooling. Serious adverse effects can include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior/ideation, respiratory depression, and withdrawal symptoms.
## Key Drug Interactions
* **CYP3A4 and CYP2C19 Inhibitors/Inducers:** Clobazam is metabolized by these enzymes. Concomitant use with strong inhibitors (e.g., fluconazole, ketoconazole) may increase clobazam levels. Strong inducers (e.g., rifampin, carbamazepine) may decrease levels.
* **CNS Depressants:** Additive CNS depression may occur with alcohol, opioids, other benzodiazepines, and other sedating medications.
* **Antiepileptic Drugs (AEDs):** Clobazam may affect the levels of other AEDs (e.g., potentially increasing levels of phenytoin, primidone, phenobarbital, and valproate; decreasing levels of lamotrigine).
## Monitoring
* Monitor for efficacy in seizure control.
* Monitor for adverse effects, especially somnolence, behavioral changes, and signs of serious skin reactions.
* Monitor for signs of withdrawal upon discontinuation.
* Therapeutic drug monitoring may be considered in specific situations, especially with concomitant medications affecting metabolism or when response is suboptimal.
## Clinical Pearls
* Clobazam is typically used as adjunctive therapy.
* Tapering is recommended upon discontinuation to minimize withdrawal symptoms.
* Due to the risk of serious skin reactions, patients should be advised to discontinue the drug and seek immediate medical attention if a rash develops.
* Clobazam is associated with a significant risk of serious adverse reactions, including somnolence, which can impair driving and operating machinery.
***
*Disclaimer: This information is intended for clinical use and does not replace comprehensive drug literature. Always verify current prescribing information with official product labeling and institutional protocols.*
